

KENYA

Support for DTP-HepB-Hib Vaccine

This Decision Letter sets out the Programme Terms of a Programme

1.	Country:	Kenya																													
2.	Vaccine grant number:	0715-KEN-04C-X, 16-KEN-04c-X, 17-KEN-04c-X, 1819-KEN-04c-X, 20-KEN-04c-X																													
3.	Date of Decision Letter:	30-Sep-2019																													
4.	Date of the Partnership Framework Agreement:	25 November 2014																													
5.	Programme title:	New Vaccine Support (NVS), DTP-HepB-Hib, Routine																													
6.	Vaccine type:	DTP-HepB-Hib																													
7.	Requested product presentation and formulation of vaccine:	Penta, 10 doses per vial, LIQUID																													
8.	Programme Duration: ¹	2001-2020																													
9.	Programme Budget (indicative): ²	(subject to the terms of the Partnership Framework Agreement, if applicable)																													
		2001-2019	2020	2021	2022	2023	2024	Total ²																							
	Programme Budget (US\$)	171,194,211	3,689,500	-	-	-	-	174,883,711																							
10.	Vaccine introduction grant	<table border="1"> <thead> <tr> <th colspan="4">Approval</th> </tr> <tr> <th>Year</th> <th>Grant Number</th> <th colspan="2">Amount (US\$)</th> </tr> </thead> <tbody> <tr> <td>2002</td> <td>n/a</td> <td colspan="2">100,000</td> </tr> <tr> <th colspan="4">Disbursement</th> </tr> <tr> <th>Disbursement date</th> <th colspan="3">Amount (US\$)</th> </tr> <tr> <td>11 February, 2002</td> <td colspan="3">100,000</td> </tr> </tbody> </table>						Approval				Year	Grant Number	Amount (US\$)		2002	n/a	100,000		Disbursement				Disbursement date	Amount (US\$)			11 February, 2002	100,000		
Approval																															
Year	Grant Number	Amount (US\$)																													
2002	n/a	100,000																													
Disbursement																															
Disbursement date	Amount (US\$)																														
11 February, 2002	100,000																														
11.	Product switch grant	Not applicable																													
12.	Indicative Annual Amounts: ³	(subject to the terms of the Partnership Framework Agreement, if applicable)																													
	Type of supplies to be purchased with Gavi funds	2001-2019	2020	2021																											

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the amount that Gavi has approved.

Number of vaccine doses		5,110,700	-																																										
Annual Amounts (US\$)	171,194,211	3,689,500	-																																										
13. Procurement agency:	UNICEF. The Country shall release its co-financing payments each year to UNICEF.																																												
14. Self-procurement:	Not applicable																																												
15. Co-financing obligations:	<p>According to the co-financing policy, the Country falls within the group: Preparatory transition phase</p> <p>The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p> <table border="1"> <thead> <tr> <th>Type of supplies to be purchased with Country funds in each year</th> <th>2020</th> <th>2021</th> <th>2022</th> <th>2023</th> <th>2024</th> </tr> </thead> <tbody> <tr> <td>Number of vaccine doses</td> <td>575,500</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> </tr> <tr> <td>Number of AD syringes</td> <td>536,400</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> </tr> <tr> <td>Number of re-constitution syringes</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> </tr> <tr> <td>Number of safety boxes</td> <td>5,925</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> </tr> <tr> <td>Value of vaccine doses (US\$)</td> <td>402,782</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> </tr> <tr> <td>Total co-financing payments (US\$) (including freight)</td> <td>440,000</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> </tr> </tbody> </table>			Type of supplies to be purchased with Country funds in each year	2020	2021	2022	2023	2024	Number of vaccine doses	575,500	-	-	-	-	Number of AD syringes	536,400	-	-	-	-	Number of re-constitution syringes	-	-	-	-	-	Number of safety boxes	5,925	-	-	-	-	Value of vaccine doses (US\$)	402,782	-	-	-	-	Total co-financing payments (US\$) (including freight)	440,000	-	-	-	-
Type of supplies to be purchased with Country funds in each year	2020	2021	2022	2023	2024																																								
Number of vaccine doses	575,500	-	-	-	-																																								
Number of AD syringes	536,400	-	-	-	-																																								
Number of re-constitution syringes	-	-	-	-	-																																								
Number of safety boxes	5,925	-	-	-	-																																								
Value of vaccine doses (US\$)	402,782	-	-	-	-																																								
Total co-financing payments (US\$) (including freight)	440,000	-	-	-	-																																								
16. Additional Reporting Requirements:	<table border="1"> <thead> <tr> <th></th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> Vaccine stock levels including buffer stock Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received </td> <td>Quarterly 15 May 2020</td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>To be agreed with Gavi Secretariat</td> </tr> </tbody> </table>				Due dates	To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> Vaccine stock levels including buffer stock Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received 	Quarterly 15 May 2020	In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat																																				
	Due dates																																												
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> Vaccine stock levels including buffer stock Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received 	Quarterly 15 May 2020																																												
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat																																												
17. Financial clarifications:	Not applicable																																												

Signed by,
On behalf of Gavi



Thabani Maphosa,
Managing Director, Country Programmes
30-Sep-2019